Novacta Biosystems (United Kingdom) a pre-clinical stage biopharmaceutical company developing anti-invectives against C. difficile, closed a $21.6M Series B financing. Participants include Celtic Pharma.

Cempra Pharmaceuticals (Chapel Hill, NC) a clinical-stage company developing antibiotics for difficult-to-treat and drug-resistant infections, closed a $46M Series C financing. Participants include Quaker BioVentures, Devon Park Bioventures, Aisling Capital, Intersouth Partners, Teachers’ Private Capital and I. Wistar Morris III.

GlycoVaxyn (Switzerland) a preclinical-stage company developing vaccines focused on bacterial caused disease, closed a $22M Series B financing. Participants include Edmond de Rothschild Investment Partners, Index Ventures and Sofinnova Partners.

Kenta Biotech (Switzerland) clinical-stage developer of antibacterial and antiviral antibodies targeting Pseudomonas aeruginosa caused nosocomial pneumonia closed a $10M Series B financing. Participants in this round have not been identified.

Mpex Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on antibiotic therapy in patients with cystic fibrosis and COPD, closed a $27.5M Series D financing. Participants include Investor Growth Capital, SV Life Sciences, HBM BioVentures, Aberdare Ventures and Adams Street Partners.

Lytix Biopharma (Norway) pre-clinical developer of lytic peptide drugs for the treatment of resistant bacterial, fungal infections and tumor progression, closed a $10.4M Series D financing.
Participants in financings have included Picasso Kapital, Såkorninvest Nord, Norinnova, Sparebanken Nord-Norge Invest, Serepta, Rekdal, Svendsen, Norinnova Invest and Taj Holding.

Affinium Pharmaceuticals (Canada) who is developing a new class of antibiotics targeting staph infections closed an $18M Series A financing. The deal was lead by Forward Ventures along with Oxford Bioscience , SV Life Sciences and Genesys Capital Partners.

Tirus Therapeutics (San Diego, CA) a biopharmaceutical company developing next generation antibacterial drugs closed a $20M Series A round. The deal was led by Sofinnova Ventures and joined by InterWest Partners, Prism VentureWorks and Versant Ventures.

Trius Therapeutics (San Diego, CA) a developer of antibacterial drugs for the treatment of a broad range of infections, raised $20M Series A financing,, The round was led by Sofinnova Ventures, InterWest Partners, Prism VentureWorks and Versant Ventures.

Targanta (Cambridge, MA) developer of antibacterial pro-drugs raised closed a $70M Series C financing led by Brookside Capital, Skyline Ventures, Radius and OrbiMed Advisors. Existing investors Seaflower Ventures, VenGrowth and the Canadian Medical Discoveries Fund also participated.